Lonza, BioWa Sign Licensing Agreement
BioWa and Lonza have entered into a licensing agreement with MedImmune for cell line technology.
BioWa and Lonza have entered into a licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca, under which MedImmune has licensed the companies’ Potelligent CHOK1SV cell line technology for use in multiple proprietary antibodies in its pipeline.
Potelligent CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines BioWa’s engineered glycosylation Potelligent technology with Lonza’s GS Gene Expression System. The GS System includes Lonza’s host cell line, CHOK1SV. Potelligent Technology is designed to improve the potency and efficacy of therapeutic antibodies by improving antibody-dependent cellular cytotoxicity (ADCC), one of the major mechanisms of therapeutic antibodies.
MedImmune entered into a previous licensing agreement with BioWa in 2007 for Potelligent Technology. Today’s agreement incorporates Lonza’s technology to the existing Potelligent Technology.
Source: Lonza
FDA Reopens Comment Period on HCP Immunogenicity Risk of Follow-on Recombinant Peptides
January 2nd 2025FDA is reopening the comment period for the Federal Register Notice, “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments”, until March 3, 2025.
